Pipeline: Stenoparib (2X-121)

Stenoparib — A Dual PARP and Tankyrase Inhibitor

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP®.

The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome.

The U.S. FDA has approved an Investigational Device Exemption (IDE) for use of the Stenoparib DRP® as a companion diagnostic in the clinical trial.

Given its novel mechanism of action and ability to cross the blood brain barrier (BBB), plus its associated DRP®, stenoparib is poised to yield improved efficacy, lower toxicity, and lower drug resistance compared the other late-stage or marketed PARP inhibitors.

Stenoparib is also being evaluated in early stage studies for its activity against COVID-19.

Sign up for press releases

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S.